Abstract | BACKGROUND: METHODS: RESULTS: Sixty-six patients with hyperlipidemia were enrolled. At the end of the study, triglyceride levels declined by 49.0% (p = 0.0002) and total cholesterol levels by 18.1% from baseline (p < 0.0001), whereas there were no significant changes observed for low-density lipoprotein- and high-density lipoprotein-cholesterol levels. Mean CD4 lymphocyte count increased from 465 cells/μL at baseline to 498 cells/μL at the end of the study, whereas the proportion of patients with undetectable plasma HIV RNA load increased from 73.1% to 81.7%. The regimens were well tolerated. CONCLUSIONS: Switch to atazanavir-containing regimens that were well tolerated resulted in significant improvement of hyperlipidemia and maintenance of clinical, immunologic, and virologic responses to CART.
|
Authors | Ching-Lan Lu, Yu-Hui Lin, Wing-Wai Wong, Hsi-Hsin Lin, Mao-Wang Ho, Ning-Chi Wang, Szu-Min Hsieh, Wang-Huei Sheng, Chien-Ching Hung, Mao-Yuan Chen |
Journal | Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
(J Microbiol Immunol Infect)
Vol. 44
Issue 4
Pg. 258-64
(Aug 2011)
ISSN: 1995-9133 [Electronic] England |
PMID | 21524961
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | Copyright © 2011. Published by Elsevier B.V. |
Chemical References |
- HIV Protease Inhibitors
- Oligopeptides
- Pyridines
- Triglycerides
- Atazanavir Sulfate
|
Topics |
- Adult
- Antiretroviral Therapy, Highly Active
(adverse effects, methods)
- Atazanavir Sulfate
- CD4 Lymphocyte Count
- Chi-Square Distribution
- Female
- HIV Infections
(blood, drug therapy)
- HIV Protease Inhibitors
(adverse effects, therapeutic use)
- HIV-1
- Humans
- Hyperlipidemias
(blood, chemically induced, virology)
- Male
- Oligopeptides
(adverse effects, therapeutic use)
- Prospective Studies
- Pyridines
(adverse effects, therapeutic use)
- Treatment Outcome
- Triglycerides
(blood)
|